134 related articles for article (PubMed ID: 34242421)
21. Unicentric or Multicentric Castleman disease? A case report of a pelvic intraperitoneal mass in a middle aged woman.
Smedile A; Capuano F; Fraticelli S; Lucioni M; La Fianza A
J Radiol Case Rep; 2019 Mar; 13(3):28-36. PubMed ID: 31565175
[TBL] [Abstract][Full Text] [Related]
22. Do six or eight cycles work better with CHOP-14 and rituximab?
Hamlin PA
Curr Oncol Rep; 2008 Sep; 10(5):391-2. PubMed ID: 18706266
[No Abstract] [Full Text] [Related]
23. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy.
Chronowski GM; Ha CS; Wilder RB; Cabanillas F; Manning J; Cox JD
Cancer; 2001 Aug; 92(3):670-6. PubMed ID: 11505414
[TBL] [Abstract][Full Text] [Related]
24. Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre.
Wang H; Wang M; Wei J; Wang L; Mao L; Jin J
J Int Med Res; 2018 Feb; 46(2):883-894. PubMed ID: 28984175
[TBL] [Abstract][Full Text] [Related]
25. Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?
Abid MB; Peck R; Abid MA; Al-Sakkaf W; Zhang Y; Dunnill GS; Staines K; Sequeiros IM; Lowry L
Hematol Oncol; 2018 Feb; 36(1):320-323. PubMed ID: 28401573
[TBL] [Abstract][Full Text] [Related]
26. Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge.
Skrabs C; Müller C; Agis H; Mannhalter C; Jäger U
Leukemia; 2002 Sep; 16(9):1884-6. PubMed ID: 12200717
[No Abstract] [Full Text] [Related]
27. Phase 3 study of frontline rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in transplantation-unsuitable mantle cell lymphoma (MCL) patients.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):9-11. PubMed ID: 25768994
[No Abstract] [Full Text] [Related]
28. Outcomes of the cyclophosphamide, vincristine, prednisone (CVP) +/- rituximab (R-CVP) regimen in older patients with newly diagnosed Ph- acute lymphoblastic leukemia.
Saygin C; Grieselhuber N; Blachly J; Byrd JC; Vasu S; Larkin K; Behbehani G; Long M; Walker A; Bhatnagar B; Mims A
Leuk Res; 2020 Feb; 89():106297. PubMed ID: 31935625
[No Abstract] [Full Text] [Related]
29. Unicentric Castleman disease presenting as a retroperitoneal peripancreatic mass: A report of two cases and review of literature.
Cheng JL; Cui J; Wang Y; Xu ZZ; Liu F; Liang SB; Tian H
World J Gastroenterol; 2018 Sep; 24(34):3958-3964. PubMed ID: 30228787
[TBL] [Abstract][Full Text] [Related]
30. Induction immunotherapy followed by surgery for hilar unicentric Castleman disease.
Shoji F; Takase K; Kozuma Y; Yamazaki K; Kawauchi S; Takeo S
Thorac Cancer; 2022 Jun; 13(11):1722-1725. PubMed ID: 35437953
[TBL] [Abstract][Full Text] [Related]
31. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
32. The Clinical and Hormonal Characteristics of Primary Adrenal Lymphomas: The Necessity of Early Detection of Adrenal Insufficiency.
Harada K; Kimura K; Iwamuro M; Terasaka T; Hanayama Y; Kondo E; Hayashi E; Yoshino T; Otsuka F
Intern Med; 2017 Sep; 56(17):2261-2269. PubMed ID: 28794358
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study.
Drach J; Huang H; Samoilova O; Belch A; Farber C; Bosly A; Novak J; Zaucha J; Dascalescu A; Bunworasate U; Masliak Z; Vilchevskaya K; Robak T; Pei L; Rooney B; van de Velde H; Cavalli F
Leuk Lymphoma; 2018 Apr; 59(4):896-903. PubMed ID: 29338540
[TBL] [Abstract][Full Text] [Related]
34. Multifocal Castleman disease in pediatrics: case report.
Baserga M; Rosin M; Schoen M; Young G
J Pediatr Hematol Oncol; 2005 Dec; 27(12):666-9. PubMed ID: 16344673
[TBL] [Abstract][Full Text] [Related]
35. Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi.
Painschab MS; Westmoreland KD; Kasonkanji E; Zuze T; Kaimila B; Waswa P; El-Mallawany NK; Tomoka T; Mulenga M; Montgomery ND; Fedoriw Y; Gopal S
Blood Adv; 2019 Feb; 3(4):612-620. PubMed ID: 30796065
[TBL] [Abstract][Full Text] [Related]
36. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
37. Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Results from a monoinstitutional cohort analysis of long-term survivors.
De Sanctis V; Alfò M; Di Rocco A; Ansuinelli M; Russo E; Osti MF; Valeriani M; Minniti G; Grapulin L; Musio D; Bracci S; Spagnoli A; Moleti ML; Tombolini V; Martelli M
Hematol Oncol; 2017 Dec; 35(4):554-560. PubMed ID: 28078727
[TBL] [Abstract][Full Text] [Related]
38. Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy.
Walter E; Schmitt T; Dietrich S; Ho A; Witzens-Harig M
Leuk Lymphoma; 2012 Nov; 53(11):2290-2. PubMed ID: 22475324
[No Abstract] [Full Text] [Related]
39. Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study.
Zhang Y; Suo SS; Yang HJ; Zhou XP; You LS; Yu WJ; Wang ZM; Jin J
J Cancer Res Clin Oncol; 2020 Feb; 146(2):357-365. PubMed ID: 31938902
[TBL] [Abstract][Full Text] [Related]
40. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
